Standards-Setting Activities of USP's Council of Experts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Standards-Setting Activities of USP's Council of Experts
This report provides plans for the USP Council's work in the 2010-2015. This articles contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 78-88

Nomenclature, Safety, and Labeling Expert Committee

The Nomenclature, Safety, and Labeling Expert Committee has responsibilities that span all Expert Committees. This Expert Committee reviews and approves USP-NF monograph titles for drug products, biologics and biotechnology products, excipients, and dietary supplements. In the 2010-2015 cycle, USP also added the focus on safety and labeling topics, formerly addressed by the Safe Medication Use Expert Committee in previous cycles.

USP has responsibility in law to create established (non-proprietary) names for drug products and to determine proper names for biologics [Section 502(e) of the Food, Drug, & Cosmetic Act (FD&C Act); FDA's policy on established names is set forth in 21 CFR, 299.4]. Along with FDA, the American Medical Association, and the American Pharmacists Association, USP participates in the US Adopted Names Council (USAN) and publishes the USP Dictionary of USAN and International Drug Names (6). USP's monograph naming approaches are outlined in general chapter Nomenclature <1121>. Additionally, a nomenclature guideline is being developed to provide supplemental information to the general approaches outlined in general chapter <1121>. The Nomenclature, Safety, and Labeling Expert Committee plans to revise general chapter <1121> to accommodate the new guideline and to make minor changes to the "Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations" (7).

The Nomenclature, Safety, and Labeling Expert Committee also has responsibility for the Medicare Model Guidelines (8) development activities, and to achieve that has appointed the Model Guidelines Expert Panel.

The Work Plan of the Nomenclature, Safety, and Labeling Expert Committee for the 2010-2015 cycle includes the following:

Naming activities. Naming activities include:

  • Approval of 300 monograph titles per year for a total of 1500 monograph titles (approximately 25-30 per month), including

-Standardized monograph titles for biologics and biotechnology drugs (including vaccines and proteins
-Standardized monograph titles for excipients
-Standardized monograph titles for dietary supplements
-Monitoring and addressing new dosage forms and other new delivery systems (e.g., nanotechnology)
-Evolving approaches of monograph naming for food ingredients in FCC
-Evolving approaches to naming non-US monographs.
  • Finalization of the Nomenclature Guideline and establishment of a nomenclature section on the USP website for title approvals, USAN information, and others
  • Updating general chapter <1121>
  • Development, with a USP Expert Panel, of an implementation, education, and communications plan for the "Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations"
  • Elaboration of approaches to encourage proper drug name pronunciation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here